Peptide Comparison

Compare peptides side-by-side.

Pick up to four peptides and compare mechanism, evidence grade, pharmacokinetics, administration and risk profile in a single view.

Selection · 3 / 4

Save & share

Save a set to reload it later on this device, or copy a share link to send the exact comparison to someone else.

Export comparison

Download the full side-by-side table as a landscape PDF for reading, or a CSV for spreadsheets and further analysis.

AI comparison summary

Biggest differences across TB-500 · GHK-Cu · BPC-157

Focused on evidence grade, pharmacokinetics, and risks/interactions — with inline citations to the primary references on each peptide page.

Click Generate summary to have AI highlight the biggest differences between the peptides you've selected.

TB-500

Grade BRegenerative

Overview

Evidence grade: Grade B
Category: Regenerative
Primary focus: Soft tissue regeneration
Summary: Widely used in veterinary medicine and reported anecdotally by athletes for muscle, tendon and ligament recovery. Human clinical data is limited to small pilot studies in dermal wound healing.

Mechanism

Mechanism of action: Synthetic fragment of Thymosin Beta-4 (residues 17–23). Binds G-actin to regulate cytoskeletal dynamics; promotes endothelial cell migration, angiogenesis, and recruitment of stem and progenitor cells to injured tissue.
Evidence explainer: Grade B — supported by preclinical evidence plus at least one small human trial, pharmacokinetic study, or strong translational rationale. Human long-term safety is incomplete.

Pharmacokinetics

Route: Subcutaneous or intramuscular injection
Half-life: ~2 hours (short systemic), with sustained tissue effects
PK notes: TB-500 is administered subcutaneous or intramuscular injection with an approximate systemic half-life of ~2 hours (short systemic), with sustained tissue effects. Steady-state and tissue-level effects can outlast plasma concentration, which is why dosing frequency (2× per week loading (4 weeks), then 2–5 mg weekly maintenance) is designed to match receptor kinetics rather than plasma exposure. Synthetic fragment of Thymosin Beta-4 (residues 17–23). Binds G-actin to regulate cytoskeletal dynamics; promotes endothelial cell migration, angiogenesis, and recruitment of stem and progenitor cells to injured tissue.

Administration

Typical dose: 2–5 mg
Frequency: 2× per week loading (4 weeks), then 2–5 mg weekly maintenance
Cycle length: 6–8 week loading phase, then maintenance
Timing: Any time of day; rotate injection sites
Protocol steps: Route: Subcutaneous or intramuscular injection. Typical starting dose 2–5 mg, 2× per week loading (4 weeks), then 2–5 mg weekly maintenance.
Timing: Any time of day; rotate injection sites — keep it the same each dosing day to make effects legible.
Cycle length: 6–8 week loading phase, then maintenance. Reassess with bloods and symptom logs before repeating.
Rotate sites across the abdomen (avoiding a 2 cm radius around the navel), outer thighs and flanks. Never inject through a bruise or mole.

Benefits

Reported benefits: Accelerated soft-tissue and tendon recovery in preclinical models
Improved range of motion after acute injury (case reports)
Wound healing and reduced fibrosis
Cardiac repair signal in animal MI models
Common stacks: BPC-157, Collagen peptides, Vitamin C

Risks

Side effects: Injection site reactions
Temporary lethargy or head rush after dosing
Long-term human safety not characterized
Contraindications: Active malignancy (theoretical angiogenic concern)
Pregnancy and lactation
Interactions: Anticoagulants — Theoretical effect on tissue remodeling — caution.
BPC-157 — Frequently co-stacked; no formal interaction studies.
Legal status: WADA-prohibited at all times (S2 class). Research chemical; not approved for human therapeutic use.

GHK-Cu

Grade CRegenerative

Overview

Evidence grade: Grade C
Category: Regenerative
Primary focus: Skin, collagen, wound repair
Summary: The important distinction almost every vendor blurs: the human evidence for GHK-Cu is topical, not injected. Small placebo-controlled facial trials show meaningful collagen gains from creams. There are no comparable trials of injected GHK-Cu, so the systemic and anti-ageing claims made for the injectable form are extrapolated from studies that used a completely different route of administration.

Mechanism

Mechanism of action: A copper-binding tripeptide — glycyl-L-histidyl-L-lysine complexed with a copper ion — that occurs naturally in plasma and falls with age. It raises TGF-beta receptor expression and amplifies SMAD2/3 signalling, increasing transcription of matrix genes including collagens, fibronectin and proteoglycans.
Evidence explainer: Grade C — mechanistic hypothesis and animal or in-vitro data only. No controlled human trials. Treat as experimental; risks are not fully known.

Pharmacokinetics

Route: Topical (where the evidence is) or subcutaneous injection (where it is not)
Half-life: Not well characterised systemically. Applied topically it acts locally; injected, plasma clearance is rapid and copper handling becomes the limiting concern.
PK notes: GHK-Cu is administered topical (where the evidence is) or subcutaneous injection (where it is not) with an approximate systemic half-life of Not well characterised systemically. Applied topically it acts locally; injected, plasma clearance is rapid and copper handling becomes the limiting concern.. Steady-state and tissue-level effects can outlast plasma concentration, which is why dosing frequency (Once or twice daily) is designed to match receptor kinetics rather than plasma exposure. A copper-binding tripeptide — glycyl-L-histidyl-L-lysine complexed with a copper ion — that occurs naturally in plasma and falls with age. It raises TGF-beta receptor expression and amplifies SMAD2/3 signalling, increasing transcription of matrix genes including collagens, fibronectin and proteoglycans.

Administration

Typical dose: Topical 1-2% cream or serum
Frequency: Once or twice daily
Cycle length: 12 weeks before judging — collagen turnover is slow
Timing: Evening, on clean skin; do not layer with vitamin C, which strips the copper
Protocol steps: Route: Topical (where the evidence is) or subcutaneous injection (where it is not). Typical starting dose Topical 1-2% cream or serum, Once or twice daily.
Timing: Evening, on clean skin; do not layer with vitamin C, which strips the copper — keep it the same each dosing day to make effects legible.
Cycle length: 12 weeks before judging — collagen turnover is slow. Reassess with bloods and symptom logs before repeating.
Rotate sites across the abdomen (avoiding a 2 cm radius around the navel), outer thighs and flanks. Never inject through a bruise or mole.

Benefits

Reported benefits: Around 28% average increase in skin collagen over 3 months in a small topical trial
Outperformed vitamin C and retinoic acid for collagen stimulation in the same comparison
Long real-world safety record as a cosmetic ingredient
Improved wound healing in controlled animal and early human work
Common stacks: Topical retinoid on alternate nights, Daily SPF, Dietary collagen or glycine

Risks

Side effects: Skin irritation or contact dermatitis in a minority of users
Copper accumulation is a theoretical concern with injected use over time
Temporary blue-green staining of skin or clothing from the copper complex
Contraindications: Wilson's disease or any disorder of copper metabolism
Known copper allergy
Pregnancy and lactation — no data
Interactions: Vitamin C (topical) — Ascorbic acid reduces the copper and inactivates the complex. Apply at different times of day.
Zinc supplementation — Zinc and copper compete for absorption; high-dose zinc can deplete copper.
Retinoids (topical) — Commonly layered, but combined irritation is the usual reason people abandon both.
Legal status: Copper tripeptide-1 is a long-established, legal cosmetic ingredient in topical products. Injectable GHK-Cu is not approved for human use in any major jurisdiction and is sold only as a research chemical.

BPC-157

Grade BRegenerative

Overview

Evidence grade: Grade B
Category: Regenerative
Primary focus: Tissue repair, gut integrity
Summary: Studied extensively in animal models for tendon, ligament, muscle, and gut mucosal healing. Human evidence is limited to small clinical observations.

Mechanism

Mechanism of action: Pentadecapeptide derived from gastric protective protein BPC. Upregulates VEGFR2, modulates nitric oxide synthesis, and accelerates angiogenesis and fibroblast migration.
Evidence explainer: Grade B — supported by preclinical evidence plus at least one small human trial, pharmacokinetic study, or strong translational rationale. Human long-term safety is incomplete.

Pharmacokinetics

Route: Subcutaneous or oral (gut-localized)
Half-life: ~15 minutes in plasma (rat IV); tissue effects far outlast it
PK notes: BPC-157 is administered subcutaneous or oral (gut-localized) with an approximate systemic half-life of ~15 minutes in plasma (rat IV); tissue effects far outlast it. Steady-state and tissue-level effects can outlast plasma concentration, which is why dosing frequency (1–2× daily) is designed to match receptor kinetics rather than plasma exposure. Pentadecapeptide derived from gastric protective protein BPC. Upregulates VEGFR2, modulates nitric oxide synthesis, and accelerates angiogenesis and fibroblast migration.

Administration

Typical dose: 250–500 mcg
Frequency: 1–2× daily
Cycle length: 4–6 weeks on, 4 weeks off
Timing: Near site of injury or AM/PM fasted
Protocol steps: Route: Subcutaneous or oral (gut-localized). Typical starting dose 250–500 mcg, 1–2× daily.
Timing: Near site of injury or AM/PM fasted — keep it the same each dosing day to make effects legible.
Cycle length: 4–6 weeks on, 4 weeks off. Reassess with bloods and symptom logs before repeating.
Rotate sites across the abdomen (avoiding a 2 cm radius around the navel), outer thighs and flanks. Never inject through a bruise or mole.

Benefits

Reported benefits: Accelerated soft-tissue recovery in preclinical models
Gut barrier integrity and ulcer protection
Potential nervous system neuroprotection
Common stacks: TB-500, Collagen peptides, Vitamin C

Risks

Side effects: Generally well tolerated in animal studies
Injection site irritation
Long-term human safety unknown
Contraindications: Active malignancy (theoretical angiogenic concern)
Pregnancy and lactation
Interactions: Anticoagulants — Theoretical synergy via NO modulation — monitor.
VEGF inhibitors — Mechanistic opposition; avoid combination.
Legal status: Not approved by the FDA for human use. Sold as a research chemical in most jurisdictions.

Attribute	TB-500 Grade BRegenerative	GHK-Cu Grade CRegenerative	BPC-157 Grade BRegenerative
Overview
Evidence grade	Grade B	Grade C	Grade B
Category	Regenerative	Regenerative	Regenerative
Primary focus	Soft tissue regeneration	Skin, collagen, wound repair	Tissue repair, gut integrity
Summary	Widely used in veterinary medicine and reported anecdotally by athletes for muscle, tendon and ligament recovery. Human clinical data is limited to small pilot studies in dermal wound healing.	The important distinction almost every vendor blurs: the human evidence for GHK-Cu is topical, not injected. Small placebo-controlled facial trials show meaningful collagen gains from creams. There are no comparable trials of injected GHK-Cu, so the systemic and anti-ageing claims made for the injectable form are extrapolated from studies that used a completely different route of administration.	Studied extensively in animal models for tendon, ligament, muscle, and gut mucosal healing. Human evidence is limited to small clinical observations.
Mechanism
Mechanism of action	Synthetic fragment of Thymosin Beta-4 (residues 17–23). Binds G-actin to regulate cytoskeletal dynamics; promotes endothelial cell migration, angiogenesis, and recruitment of stem and progenitor cells to injured tissue.	A copper-binding tripeptide — glycyl-L-histidyl-L-lysine complexed with a copper ion — that occurs naturally in plasma and falls with age. It raises TGF-beta receptor expression and amplifies SMAD2/3 signalling, increasing transcription of matrix genes including collagens, fibronectin and proteoglycans.	Pentadecapeptide derived from gastric protective protein BPC. Upregulates VEGFR2, modulates nitric oxide synthesis, and accelerates angiogenesis and fibroblast migration.
Evidence explainer	Grade B — supported by preclinical evidence plus at least one small human trial, pharmacokinetic study, or strong translational rationale. Human long-term safety is incomplete.	Grade C — mechanistic hypothesis and animal or in-vitro data only. No controlled human trials. Treat as experimental; risks are not fully known.	Grade B — supported by preclinical evidence plus at least one small human trial, pharmacokinetic study, or strong translational rationale. Human long-term safety is incomplete.
Pharmacokinetics
Route	Subcutaneous or intramuscular injection	Topical (where the evidence is) or subcutaneous injection (where it is not)	Subcutaneous or oral (gut-localized)
Half-life	~2 hours (short systemic), with sustained tissue effects	Not well characterised systemically. Applied topically it acts locally; injected, plasma clearance is rapid and copper handling becomes the limiting concern.	~15 minutes in plasma (rat IV); tissue effects far outlast it
PK notes	TB-500 is administered subcutaneous or intramuscular injection with an approximate systemic half-life of ~2 hours (short systemic), with sustained tissue effects. Steady-state and tissue-level effects can outlast plasma concentration, which is why dosing frequency (2× per week loading (4 weeks), then 2–5 mg weekly maintenance) is designed to match receptor kinetics rather than plasma exposure. Synthetic fragment of Thymosin Beta-4 (residues 17–23). Binds G-actin to regulate cytoskeletal dynamics; promotes endothelial cell migration, angiogenesis, and recruitment of stem and progenitor cells to injured tissue.	GHK-Cu is administered topical (where the evidence is) or subcutaneous injection (where it is not) with an approximate systemic half-life of Not well characterised systemically. Applied topically it acts locally; injected, plasma clearance is rapid and copper handling becomes the limiting concern.. Steady-state and tissue-level effects can outlast plasma concentration, which is why dosing frequency (Once or twice daily) is designed to match receptor kinetics rather than plasma exposure. A copper-binding tripeptide — glycyl-L-histidyl-L-lysine complexed with a copper ion — that occurs naturally in plasma and falls with age. It raises TGF-beta receptor expression and amplifies SMAD2/3 signalling, increasing transcription of matrix genes including collagens, fibronectin and proteoglycans.	BPC-157 is administered subcutaneous or oral (gut-localized) with an approximate systemic half-life of ~15 minutes in plasma (rat IV); tissue effects far outlast it. Steady-state and tissue-level effects can outlast plasma concentration, which is why dosing frequency (1–2× daily) is designed to match receptor kinetics rather than plasma exposure. Pentadecapeptide derived from gastric protective protein BPC. Upregulates VEGFR2, modulates nitric oxide synthesis, and accelerates angiogenesis and fibroblast migration.
Administration
Typical dose	2–5 mg	Topical 1-2% cream or serum	250–500 mcg
Frequency	2× per week loading (4 weeks), then 2–5 mg weekly maintenance	Once or twice daily	1–2× daily
Cycle length	6–8 week loading phase, then maintenance	12 weeks before judging — collagen turnover is slow	4–6 weeks on, 4 weeks off
Timing	Any time of day; rotate injection sites	Evening, on clean skin; do not layer with vitamin C, which strips the copper	Near site of injury or AM/PM fasted
Protocol steps	Route: Subcutaneous or intramuscular injection. Typical starting dose 2–5 mg, 2× per week loading (4 weeks), then 2–5 mg weekly maintenance. Timing: Any time of day; rotate injection sites — keep it the same each dosing day to make effects legible. Cycle length: 6–8 week loading phase, then maintenance. Reassess with bloods and symptom logs before repeating. Rotate sites across the abdomen (avoiding a 2 cm radius around the navel), outer thighs and flanks. Never inject through a bruise or mole.	Route: Topical (where the evidence is) or subcutaneous injection (where it is not). Typical starting dose Topical 1-2% cream or serum, Once or twice daily. Timing: Evening, on clean skin; do not layer with vitamin C, which strips the copper — keep it the same each dosing day to make effects legible. Cycle length: 12 weeks before judging — collagen turnover is slow. Reassess with bloods and symptom logs before repeating. Rotate sites across the abdomen (avoiding a 2 cm radius around the navel), outer thighs and flanks. Never inject through a bruise or mole.	Route: Subcutaneous or oral (gut-localized). Typical starting dose 250–500 mcg, 1–2× daily. Timing: Near site of injury or AM/PM fasted — keep it the same each dosing day to make effects legible. Cycle length: 4–6 weeks on, 4 weeks off. Reassess with bloods and symptom logs before repeating. Rotate sites across the abdomen (avoiding a 2 cm radius around the navel), outer thighs and flanks. Never inject through a bruise or mole.
Benefits
Reported benefits	Accelerated soft-tissue and tendon recovery in preclinical models Improved range of motion after acute injury (case reports) Wound healing and reduced fibrosis Cardiac repair signal in animal MI models	Around 28% average increase in skin collagen over 3 months in a small topical trial Outperformed vitamin C and retinoic acid for collagen stimulation in the same comparison Long real-world safety record as a cosmetic ingredient Improved wound healing in controlled animal and early human work	Accelerated soft-tissue recovery in preclinical models Gut barrier integrity and ulcer protection Potential nervous system neuroprotection
Common stacks	BPC-157, Collagen peptides, Vitamin C	Topical retinoid on alternate nights, Daily SPF, Dietary collagen or glycine	TB-500, Collagen peptides, Vitamin C
Risks
Side effects	Injection site reactions Temporary lethargy or head rush after dosing Long-term human safety not characterized	Skin irritation or contact dermatitis in a minority of users Copper accumulation is a theoretical concern with injected use over time Temporary blue-green staining of skin or clothing from the copper complex	Generally well tolerated in animal studies Injection site irritation Long-term human safety unknown
Contraindications	Active malignancy (theoretical angiogenic concern) Pregnancy and lactation	Wilson's disease or any disorder of copper metabolism Known copper allergy Pregnancy and lactation — no data	Active malignancy (theoretical angiogenic concern) Pregnancy and lactation
Interactions	Anticoagulants — Theoretical effect on tissue remodeling — caution. BPC-157 — Frequently co-stacked; no formal interaction studies.	Vitamin C (topical) — Ascorbic acid reduces the copper and inactivates the complex. Apply at different times of day. Zinc supplementation — Zinc and copper compete for absorption; high-dose zinc can deplete copper. Retinoids (topical) — Commonly layered, but combined irritation is the usual reason people abandon both.	Anticoagulants — Theoretical synergy via NO modulation — monitor. VEGF inhibitors — Mechanistic opposition; avoid combination.
Legal status	WADA-prohibited at all times (S2 class). Research chemical; not approved for human therapeutic use.	Copper tripeptide-1 is a long-established, legal cosmetic ingredient in topical products. Injectable GHK-Cu is not approved for human use in any major jurisdiction and is sold only as a research chemical.	Not approved by the FDA for human use. Sold as a research chemical in most jurisdictions.

← Back to all peptides